Durham, United States
Incyclix Bio, a pioneer founded in 2020, is at the forefront of biotechnology innovation with its next-generation approach in cell cycle control. Under the slogan "Regaining Cell Cycle Control", the company is committed to developing precision treatments targeting the aberrant proliferation that is a hallmark of many cancers.
Headquartered in Research Triangle Park, NC, United States, Incyclix Bio focuses on advancing its lead compound, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, towards clinical stages. This compound positions the company as a scientific leader, especially in targeting cyclin-dependent kinases (CDKs) which play a crucial role across many tumor types, including ovarian, breast, and lung cancers.
Recently, Incyclix Bio secured a $5.00M Series B investment on 01 April 2026. Esteemed investors include RA Capital Management, Hatteras Venture Partners, Boxer Capital, Eli Lilly, Eshelman Ventures, Pharmacosmos, and Cape Fear BioCapital.
